Quantcast
Last updated on April 23, 2014 at 10:50 EDT

Latest NMDA receptor Stories

2013-06-04 08:28:46

New NMDA Receptor Modulator Is Orally Available Follow-on to Rapidly-Acting Lead Compound GLYX-13 EVANSTON, Ill., June 4, 2013 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has begun patient dosing in a Phase I trial of its novel, orally active agent NRX-1074. NRX-1074 is a follow-on to Naurex's first-generation compound GLYX-13, which has demonstrated good safety,...

2013-05-29 09:48:10

For several years, the pharmaceutical industry has tried to develop drugs that target a specific neurotransmitter receptor in the brain, the NMDA receptor. This receptor is present on almost every neuron in the human brain and is involved in learning and memory. NMDA receptors also have been implicated in several neurological and psychiatric conditions such as Alzheimer's disease, Parkinson's disease, schizophrenia and depression. But drug companies have had little success developing...

2013-04-19 12:27:01

BALTIMORE, April 19, 2013 /PRNewswire/ -- Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression. There is a growing body...

2013-04-04 11:39:35

The gene variants weaken the same receptors that some hallucinogenic drugs block New genetic factors predisposing to schizophrenia have been uncovered in five families with several affected relatives. The psychiatric disorder can disrupt thinking, feeling, and acting, and blur the border between reality and imagination. Dr. Debby W. Tsuang, professor of psychiatry and behavioral sciences, and Dr. Marshall S. Horwitz, professor of pathology, both at the University of Washington in...

2013-03-14 17:57:23

Since the 1960s, psychiatrists have been hunting for substances made by the body that might accumulate in abnormally high levels to produce the symptoms associated with schizophrenia. In particular, there was a search for chemicals that might be related to the hallucinogens phencyclidine (PCP) or lysergic acid diethylamide (LSD), which could explain the emergence of psychotic symptoms in schizophrenia. This "auto-intoxication" hypothesis led investigators on a wild goose chase where...

2013-01-01 10:47:31

Jackson Laboratory researchers led by Associate Professor Zhong-wei Zhang, Ph.D., have provided direct evidence that a specific neurotransmitter receptor is vital to the process of pruning synapses in the brains of newborn mammals. Faulty pruning at this early developmental stage is implicated in autism-spectrum disorders and schizophrenia. The definitive evidence for N-methyl-D-aspartate receptor (NMDAR) in pruning has eluded researchers until now, but in research published in the...

2012-12-13 12:29:17

Works in brain like ketamine, with fewer side effects -- NIH trial A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system. Existing antidepressants available through...

2012-08-07 23:17:46

Biomarkers help pinpoint mechanisms, predict outcomes -- NIH studies Scientists have discovered a biological marker that may help to identify which depressed patients will respond to an experimental, rapid-acting antidepressant. The brain signal, detectable by noninvasive imaging, also holds clues to the agent's underlying mechanism, which are vital for drug development, say National Institutes of Health researchers. The signal is among the latest of several such markers, including...

2012-02-21 14:06:49

Researchers at the University of Copenhagen have designed, produced and patented a new chemical compound for the possible treatment of brain damage caused by stroke. The compound binds 1,000 times more effectively to the target protein in the brain than the potential drug currently being tested on stroke victims. The results of biological tests have just been published in the renowned journal PNAS. More than 140,000 people die each year from stroke in the United States. Stroke causes the...

2012-02-21 06:46:00

BANGALORE, India, February 21, 2012 /PRNewswire/ -- Jubilant Biosys Limited, Bangalore announced today that they have entered into drug discovery collaboration with Mnemosyne Pharmaceutical Inc, Providence, Rhode Island that will seek to identify preclinical candidates in the area of neuropsychiatric diseases. The collaboration will focus on developing subunit selective NMDA receptor modulators (SNRMs) that Mnemosyne has identified. The alliance shall initially span a period of...